Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Re-ups 10-year NIH contract to support the Blueprint Neurotherapeutics Network
April 20, 2018
By: Tim Wright
Editor-in-Chief, Contract Pharma
AMRI has won renewal of a 10-year contract worth up to $39.5 million with the National Institutes of Health (NIH) Blueprint Neurotherapeutics Network (BPN). This renewal means AMRI will continue to provide the BPN with medicinal chemistry and ADME services focused on advancing drug discovery programs in neurotherapeutics. The original award for this work was made to AMRI in 2011. The BPN provides non-dilutive support for small molecule drug discovery and development for companies and academic researchers looking to develop new medicines to treat nervous system disorders. The program gives successful applicants access to NIH-funded contract research organizations (CROs) like AMRI for outsourced discovery solutions. Services supported by this contract will include exploratory chemistry, hit-to-lead and lead optimization efforts, including structure-activity-relationship (SAR) analysis and design, synthesis, in vitro ADMET studies, and computer-aided drug discovery. Under this new award, the National Institute of Neurological Disorders and Stroke (NINDS), which manages the BPN, now also has the opportunity to leverage AMRI’s additional capacity and medicinal chemistry capabilities at its state-of-the-art Drug Discovery Center of Excellence in Buffalo, New York. “The NINDS contract renewal is a testament to AMRI’s reputation as a trusted partner in drug discovery, its proven track record, commitment to excellence and customer focus,” said Chris Conway, senior vice president and head of drug discovery, chemical development and analytical services, AMRI. “AMRI is excited to continue building upon our long-standing relationship with the NIH. We fully support the BPN’s mission of aiding scientists working in disease areas with unmet needs through the provision of experienced consultants and top-notch CRO support.” “We look forward to continuing our successful BPN collaboration with AMRI and hope the services and support they provide to our scientists will help accelerate the development of novel therapies for a wide range of neurological disorders,” said Charles Cywin, program director, NINDS. In addition to this latest award, AMRI has three other prime contracts with the NIH and serves as a dedicated center for the National Cancer Institute’s (NCI) Chemical Biology Consortium (CBC), providing medicinal chemistry, compound profiling, in vitro ADMET, protein biochemistry, cancer cell biology and preclinical development services, as needed. AMRI’s participation in the CBC is through a subcontract with Leidos Biomedical Research, Inc., the prime contractor for NCI’s Frederick National Lab for Cancer Research.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !